Symbols / TPST Stock $1.85 +4.52% Tempest Therapeutics, Inc.
TPST (Stock) Chart
About
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Stock Fundamentals
Scroll to Statements| Market Cap | 26.54M | Enterprise Value | 26.97M | Income | -26.26M | Sales | — | Book/sh | 1.35 | Cash/sh | 0.54 |
| Dividend Yield | — | Payout | 0.00% | Employees | 4 | IPO | — | P/E | — | Forward P/E | -1.53 |
| PEG | — | P/S | — | P/B | 1.37 | P/C | — | EV/EBITDA | -1.02 | EV/Sales | — |
| Quick Ratio | 2.33 | Current Ratio | 2.50 | Debt/Eq | 122.09 | LT Debt/Eq | — | EPS (ttm) | -6.33 | EPS next Y | -1.21 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-13 | ROA | -56.86% | ROE | -203.63% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 14.34M | Shs Float | 9.27M | Short Float | 7.78% |
| Short Ratio | 2.41 | Short Interest | — | 52W High | 12.23 | 52W Low | 1.50 | Beta | -1.89 | Avg Volume | 203.17K |
| Volume | 162.73K | Target Price | $11.00 | Recom | None | Prev Close | $1.77 | Price | $1.85 | Change | 4.52% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-22 | up | HC Wainwright & Co. | Neutral → Buy | $11 |
| 2025-04-10 | down | Scotiabank | Sector Outperform → Sector Perform | $9 |
| 2025-04-10 | down | HC Wainwright & Co. | Buy → Neutral | $16 |
| 2025-03-28 | main | Scotiabank | Sector Outperform → Sector Outperform | $7 |
| 2025-03-28 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-11-13 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2024-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-06-21 | reit | Piper Sandler | Overweight → Overweight | $8 |
| 2024-06-20 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-05-10 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-03-20 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-03-14 | init | Scotiabank | — → Sector Outperform | $13 |
| 2024-03-13 | init | Scotiabank | — → Sector Outperform | $13 |
| 2024-03-12 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2024-02-08 | init | Jefferies | — → Buy | $15 |
| 2023-10-11 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
- After 6 of 6 complete responses, Tempest moves toward pivotal CAR-T study - Stock Titan Wed, 22 Apr 2026 12
- TPST Forecast, Price Target & Analyst Ratings | TEMPEST THERAPEUTICS INC (NASDAQ:TPST) - ChartMill Fri, 17 Apr 2026 07
- Tempest Therapeutics (TPST) Advances Dual-Targeting CAR-T Therap - GuruFocus Wed, 22 Apr 2026 14
- $TPST stock is up 28% today. Here's what we see in our data. - Quiver Quantitative Fri, 10 Apr 2026 07
- Tempest Therapeutics provides update on development of TPST-2003 - TipRanks Wed, 22 Apr 2026 23
- Tempest Therapeutics (TPST) Stock: Why Spinoff Value (Tick Down) 2026-04-20 - Social Flow Trades - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 09
- Tempest brings in China dealmaker for Phase 3-ready cancer drug - Stock Titan ue, 14 Apr 2026 12
- Cancer biotech Tempest retools around dual CAR-Ts and new CEO - Stock Titan Wed, 04 Feb 2026 08
- Cancer drug developer Tempest to hand out 1:1 stock warrants - Stock Titan ue, 20 Jan 2026 08
- Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan hu, 02 Apr 2026 07
- Tempest's new CEO arrives as six myeloma patients hit complete response - Stock Titan Mon, 30 Mar 2026 07
- Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan Fri, 10 Apr 2026 07
- Tempest myeloma cell therapy hits 100% response in 25 patients, US trial planned - Stock Titan Wed, 25 Feb 2026 08
- [EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan hu, 09 Apr 2026 07
- Cancer drug developer Tempest lines up up to $6M in funding - Stock Titan Mon, 23 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
26.57
-36.77%
|
42.03
+44.14%
|
29.16
-15.83%
|
34.64
|
| Research And Development |
|
12.61
-55.73%
|
28.48
+62.74%
|
17.50
-22.32%
|
22.53
|
| Selling General And Administration |
|
13.97
+3.09%
|
13.55
+16.22%
|
11.66
-3.75%
|
12.11
|
| General And Administrative Expense |
|
13.97
+3.09%
|
13.55
+16.22%
|
11.66
-3.75%
|
12.11
|
| Other Gand A |
|
13.97
+3.09%
|
13.55
+16.22%
|
11.66
-3.75%
|
12.11
|
| Total Expenses |
|
26.57
-36.77%
|
42.03
+44.14%
|
29.16
-15.83%
|
34.64
|
| Operating Income |
|
-26.57
+36.77%
|
-42.03
-44.14%
|
-29.16
+15.83%
|
-34.64
|
| Total Operating Income As Reported |
|
-26.57
+36.77%
|
-42.03
-44.14%
|
-29.16
+15.83%
|
-34.64
|
| EBITDA |
|
-25.79
+35.75%
|
-40.14
-45.11%
|
-27.66
+17.31%
|
-33.45
|
| Normalized EBITDA |
|
-25.79
+35.75%
|
-40.14
-45.11%
|
-27.66
+17.31%
|
-33.45
|
| Reconciled Depreciation |
|
0.27
-31.62%
|
0.39
+2.10%
|
0.38
-40.28%
|
0.64
|
| EBIT |
|
-26.05
+35.71%
|
-40.53
-44.52%
|
-28.04
+17.74%
|
-34.09
|
| Net Income |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Pretax Income |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Net Non Operating Interest Income Expense |
|
0.31
+71.04%
|
0.18
+154.79%
|
-0.33
+67.19%
|
-1.02
|
| Interest Expense Non Operating |
|
0.21
-84.27%
|
1.32
-9.18%
|
1.45
-10.44%
|
1.62
|
| Net Interest Income |
|
0.31
+71.04%
|
0.18
+154.79%
|
-0.33
+67.19%
|
-1.02
|
| Interest Expense |
|
0.21
-84.27%
|
1.32
-9.18%
|
1.45
-10.44%
|
1.62
|
| Interest Income Non Operating |
|
0.52
-65.31%
|
1.50
+34.44%
|
1.11
+85.83%
|
0.60
|
| Interest Income |
|
0.52
-65.31%
|
1.50
+34.44%
|
1.11
+85.83%
|
0.60
|
| Other Income Expense |
|
—
|
—
|
0.01
+129.41%
|
-0.05
|
| Other Non Operating Income Expenses |
|
—
|
—
|
0.01
+129.41%
|
-0.05
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Net Income From Continuing Operation Net Minority Interest |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Net Income From Continuing And Discontinued Operation |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Net Income Continuous Operations |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Normalized Income |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Net Income Common Stockholders |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Diluted EPS |
|
—
|
-19.50
+21.47%
|
-24.83
+38.19%
|
-40.17
|
| Basic EPS |
|
—
|
-19.50
+21.47%
|
-24.83
+38.19%
|
-40.17
|
| Basic Average Shares |
|
—
|
3.38
+185.23%
|
1.19
+33.40%
|
0.89
|
| Diluted Average Shares |
|
—
|
3.38
+185.23%
|
1.19
+33.40%
|
0.89
|
| Diluted NI Availto Com Stockholders |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
16.93
-59.19%
|
41.49
-19.60%
|
51.60
+11.96%
|
46.09
|
| Current Assets |
|
8.27
-73.73%
|
31.47
-22.02%
|
40.36
+22.50%
|
32.95
|
| Cash Cash Equivalents And Short Term Investments |
|
7.71
-74.54%
|
30.27
-22.84%
|
39.23
+25.62%
|
31.23
|
| Cash And Cash Equivalents |
|
7.71
-74.54%
|
30.27
-22.84%
|
39.23
+25.62%
|
31.23
|
| Receivables |
|
—
|
—
|
0.00
-100.00%
|
0.45
|
| Other Receivables |
|
—
|
—
|
—
|
0.45
|
| Prepaid Assets |
|
0.21
-69.15%
|
0.67
-35.29%
|
1.04
+2.98%
|
1.01
|
| Other Current Assets |
|
0.35
-33.64%
|
0.54
+457.29%
|
0.10
-63.50%
|
0.26
|
| Total Non Current Assets |
|
8.66
-13.50%
|
10.01
-10.91%
|
11.24
-14.45%
|
13.14
|
| Net PPE |
|
8.14
-14.52%
|
9.53
-11.70%
|
10.79
-15.09%
|
12.71
|
| Gross PPE |
|
9.60
-11.53%
|
10.85
-8.19%
|
11.82
-16.02%
|
14.07
|
| Accumulated Depreciation |
|
-1.45
-10.08%
|
-1.32
-28.78%
|
-1.02
+24.69%
|
-1.36
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Buildings And Improvements |
|
—
|
—
|
9.95
-14.58%
|
11.65
|
| Machinery Furniture Equipment |
|
0.41
-20.38%
|
0.52
+4.63%
|
0.50
+3.97%
|
0.48
|
| Other Properties |
|
8.99
-11.28%
|
10.13
-8.63%
|
11.09
+944.77%
|
1.06
|
| Leases |
|
0.20
-1.49%
|
0.20
-14.47%
|
0.23
-73.36%
|
0.88
|
| Other Non Current Assets |
|
0.52
+6.60%
|
0.48
+8.26%
|
0.45
+4.43%
|
0.43
|
| Total Liabilities Net Minority Interest |
|
10.26
-54.11%
|
22.36
-9.96%
|
24.84
-11.23%
|
27.98
|
| Current Liabilities |
|
3.31
-76.69%
|
14.22
+51.10%
|
9.41
+29.33%
|
7.28
|
| Payables And Accrued Expenses |
|
1.98
-62.27%
|
5.24
+98.97%
|
2.63
-43.00%
|
4.62
|
| Payables |
|
1.04
-57.63%
|
2.45
+189.94%
|
0.84
-23.74%
|
1.11
|
| Accounts Payable |
|
1.04
-57.63%
|
2.45
+189.94%
|
0.84
-23.74%
|
1.11
|
| Current Accrued Expenses |
|
0.94
-66.36%
|
2.79
+55.94%
|
1.79
-49.09%
|
3.51
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.15
-91.66%
|
1.76
+14.19%
|
1.54
+23.64%
|
1.25
|
| Current Debt And Capital Lease Obligation |
|
1.19
-83.50%
|
7.22
+37.92%
|
5.24
+270.63%
|
1.41
|
| Current Debt |
|
—
|
6.35
+48.28%
|
4.29
|
—
|
| Other Current Borrowings |
|
—
|
6.35
+48.28%
|
4.29
|
—
|
| Current Capital Lease Obligation |
|
1.19
+37.17%
|
0.87
-8.72%
|
0.95
-32.63%
|
1.41
|
| Total Non Current Liabilities Net Minority Interest |
|
6.95
-14.65%
|
8.14
-47.21%
|
15.42
-25.49%
|
20.70
|
| Long Term Debt And Capital Lease Obligation |
|
6.95
-14.65%
|
8.14
-47.21%
|
15.42
-25.49%
|
20.70
|
| Long Term Debt |
|
—
|
—
|
6.26
-39.60%
|
10.37
|
| Long Term Capital Lease Obligation |
|
6.95
-14.65%
|
8.14
-11.11%
|
9.16
-11.33%
|
10.33
|
| Preferred Securities Outside Stock Equity |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
6.67
-65.14%
|
19.13
-28.55%
|
26.77
+47.80%
|
18.11
|
| Common Stock Equity |
|
6.67
-65.14%
|
19.13
-28.55%
|
26.77
+47.80%
|
18.11
|
| Capital Stock |
|
0.01
+66.67%
|
0.00
-86.36%
|
0.02
+100.00%
|
0.01
|
| Common Stock |
|
0.01
+66.67%
|
0.00
-86.36%
|
0.02
+100.00%
|
0.01
|
| Share Issued |
|
4.93
+45.67%
|
3.38
+99.46%
|
1.70
+109.58%
|
0.81
|
| Ordinary Shares Number |
|
4.93
+45.67%
|
3.38
+99.46%
|
1.70
+109.58%
|
0.81
|
| Additional Paid In Capital |
|
240.03
+6.10%
|
226.23
+17.82%
|
192.01
+24.78%
|
153.87
|
| Retained Earnings |
|
-233.37
-12.68%
|
-207.11
-25.32%
|
-165.26
-21.72%
|
-135.77
|
| Total Equity Gross Minority Interest |
|
6.67
-65.14%
|
19.13
-28.55%
|
26.77
+47.80%
|
18.11
|
| Total Capitalization |
|
6.67
-65.14%
|
19.13
-42.10%
|
33.03
+15.98%
|
28.48
|
| Working Capital |
|
4.96
-71.28%
|
17.25
-44.26%
|
30.95
+20.56%
|
25.67
|
| Invested Capital |
|
6.67
-73.83%
|
25.48
-31.72%
|
37.32
+31.02%
|
28.48
|
| Total Debt |
|
8.14
-47.02%
|
15.37
-25.63%
|
20.66
-6.57%
|
22.11
|
| Capital Lease Obligations |
|
8.14
-9.65%
|
9.01
-10.89%
|
10.11
-13.89%
|
11.74
|
| Net Tangible Assets |
|
6.67
-65.14%
|
19.13
-28.55%
|
26.77
+47.80%
|
18.11
|
| Tangible Book Value |
|
6.67
-65.14%
|
19.13
-28.55%
|
26.77
+47.80%
|
18.11
|
| Interest Payable |
|
0.00
-100.00%
|
0.06
-47.79%
|
0.11
+16.49%
|
0.10
|
| Notes Receivable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-26.82
+18.79%
|
-33.03
-20.73%
|
-27.36
+11.96%
|
-31.07
|
| Cash Flow From Continuing Operating Activities |
|
-26.82
+18.79%
|
-33.03
-20.73%
|
-27.36
+11.96%
|
-31.07
|
| Net Income From Continuing Operations |
|
-26.26
+37.24%
|
-41.84
-41.88%
|
-29.49
+17.41%
|
-35.71
|
| Depreciation Amortization Depletion |
|
0.27
-31.62%
|
0.39
+2.10%
|
0.38
-40.28%
|
0.64
|
| Depreciation |
|
0.27
-31.62%
|
0.39
+2.10%
|
0.38
-40.28%
|
0.64
|
| Depreciation And Amortization |
|
0.27
-31.62%
|
0.39
+2.10%
|
0.38
-40.28%
|
0.64
|
| Other Non Cash Items |
|
1.19
-21.38%
|
1.51
-19.80%
|
1.88
+20.00%
|
1.57
|
| Stock Based Compensation |
|
3.12
-41.20%
|
5.30
+108.29%
|
2.55
+63.10%
|
1.56
|
| Change In Working Capital |
|
-5.13
-418.04%
|
1.61
+160.25%
|
-2.68
-408.41%
|
0.87
|
| Change In Prepaid Assets |
|
0.61
+659.09%
|
-0.11
-156.99%
|
0.19
-78.91%
|
0.92
|
| Change In Payables And Accrued Expense |
|
-4.88
-272.63%
|
2.82
+327.93%
|
-1.24
-185.21%
|
1.45
|
| Change In Accrued Expense |
|
-3.46
-384.09%
|
1.22
+224.90%
|
-0.98
-167.17%
|
1.45
|
| Change In Payable |
|
-1.41
-187.98%
|
1.60
+710.27%
|
-0.26
-26400.00%
|
0.00
|
| Change In Account Payable |
|
-1.41
-187.98%
|
1.60
+710.27%
|
-0.26
-26400.00%
|
0.00
|
| Change In Other Current Liabilities |
|
-0.87
+20.98%
|
-1.10
+32.50%
|
-1.63
-8.66%
|
-1.50
|
| Investing Cash Flow |
|
0.00
+100.00%
|
-0.43
-155.88%
|
-0.17
+69.75%
|
-0.56
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-0.43
-155.88%
|
-0.17
+69.75%
|
-0.56
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.43
-155.88%
|
-0.17
+69.75%
|
-0.56
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.43
-155.88%
|
-0.17
+69.75%
|
-0.56
|
| Capital Expenditure |
|
—
|
-0.43
-155.88%
|
-0.17
+69.75%
|
-0.56
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
4.26
-82.62%
|
24.50
-31.18%
|
35.60
+212.22%
|
11.40
|
| Cash Flow From Continuing Financing Activities |
|
4.26
-82.62%
|
24.50
-31.18%
|
35.60
+212.22%
|
11.40
|
| Net Issuance Payments Of Debt |
|
-6.43
-46.11%
|
-4.40
|
0.00
+100.00%
|
-4.74
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
-6.43
-46.11%
|
-4.40
|
0.00
+100.00%
|
-4.74
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
-6.43
-46.11%
|
-4.40
|
0.00
+100.00%
|
-4.74
|
| Net Long Term Debt Issuance |
|
-6.43
-46.11%
|
-4.40
|
0.00
+100.00%
|
-4.74
|
| Net Common Stock Issuance |
|
7.33
-74.37%
|
28.59
-19.69%
|
35.60
+301.78%
|
8.86
|
| Proceeds From Stock Option Exercised |
|
3.36
+993.16%
|
0.31
|
0.00
-100.00%
|
7.28
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
-22.56
-151.74%
|
-8.96
-210.98%
|
8.07
+139.91%
|
-20.23
|
| Beginning Cash Position |
|
30.71
-22.59%
|
39.67
+25.56%
|
31.60
-39.03%
|
51.83
|
| End Cash Position |
|
8.15
-73.46%
|
30.71
-22.59%
|
39.67
+25.56%
|
31.60
|
| Free Cash Flow |
|
-26.82
+19.85%
|
-33.46
-21.56%
|
-27.53
+12.98%
|
-31.63
|
| Interest Paid Supplemental Data |
|
0.19
-83.69%
|
1.18
-5.76%
|
1.25
-18.84%
|
1.54
|
| Income Tax Paid Supplemental Data |
|
0.04
-20.37%
|
0.05
-71.73%
|
0.19
+961.11%
|
0.02
|
| Change In Interest Payable |
|
-0.06
-9.26%
|
-0.05
-437.50%
|
0.02
+106.25%
|
-0.26
|
| Common Stock Issuance |
|
7.33
-74.37%
|
28.59
-19.69%
|
35.60
+301.78%
|
8.86
|
| Issuance Of Capital Stock |
|
7.33
-74.37%
|
28.59
-19.69%
|
35.60
+301.78%
|
8.86
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
7.28
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
7.28
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-02 View
- 42026-04-02 View
- 10-K2026-03-30 View
- 8-K2026-03-30 View
- 42026-03-25 View
- 8-K2026-03-23 View
- 8-K2026-02-25 View
- 8-K2026-02-11 View
- 42026-02-06 View
- 8-K2026-02-06 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 42026-01-28 View
- 8-K2026-01-28 View
- 8-K2026-01-09 View
- 8-K2025-11-26 View
- 8-K2025-11-19 View
- 10-Q2025-11-05 View
- 8-K2025-11-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|